ANAVEX. NY TRÅD NY TRÅD over 100 % indrulning i Alzheimer!
-
Tror at en stor del af forklaringen på SAVA's kurshop de seneste par dage skyldes store forventninger til resultaterne de præsenterer på AAIC i næste uge, se
https://finance.yahoo.com/news/cassava-sciences-present-clinical-dataset-123000732.html -
Læs dette Ihub indlæg af min yndlingsskribent
Anavex Life Sciences Corp (AVXL): Anavex Headed for Greatness http://ww...
falconer66a: Anavex Headed for Greatness http://www.anavex.com/wp-content/uploads/2021/07/Anavex-Presentation-July-2021.pdf Postings have been made about the...
InvestorsHub (investorshub.advfn.com)
Han og Tasso1 har set lyset i Anavex seneste virsomhedspræsentation
-
Ja, manden lyder MEGET overbevisende
"Consider; the information presented in the new Anavex presentation shows that blarcamesine beats, by a long margin, any and all other drugs now used to treat the listed CNS diseases. Blarcamesine has no competition. The few other drugs treating CNS diseases work against "downstream" disease processes and outcomes; and not very well. Blarcamesine, by itself, is in a whole new CNS drug category, where by its profound activation of the sigma-1 receptor protein, "upstream" in neuropathology reaction pathways, a diversity of downstream pathologies are "fixed," obviated. No other drug like it"
Som alt man læser på diverse netfora, er det jo vigtigt at bevare en vis portion sund skepsis
Hvad er mandens baggrund (faglige kompetence) for at kunne udtale sig så bastant?Disclaimer. Jeg har selv en ret pæn portion AVXL og tror også på at de sidder inde med en blandt flere nye behandlingsmuligheder af Alzheimer' o.a. CNS lidelser, men ....
-
Solsen, jeg lavede lige en paste & kopi.
Ja ham Falconer er meget dygtig.
falconer66a Tuesday, 07/20/21 09:34:51 PM
Re: georgejjl post# 321945 0
Post # of 322045Anavex Headed for Greatness
Postings have been made about the virtual silence of both Anavex Life Sciences Corp and its CEO, Dr. Christopher Missling. That silence has ended with today's new presentation. Nothing will be heard from it; it has to be closely read and understood. Missling and company have put together their most important, most definitive presentation ever.
There is not a shadow of doubt concerning the profoundly positive results that all of the three on-going clinical trials will generate. First, the girls with Rett syndrome will gain significant symptomatic relief. Then, in the Parkinson's disease dementia study cognition will be at least maintained, or in most cases even recovered to some degree. Finally, Alzheimer's will be very successfully treated with blarcamesine (and probably prevented).
How can these claims of clinical success be confidently made? Simple. There has never been a clinical failure of blarcamesine, either in the many pre-clinical murine (lab rodent) tests, nor in any early-stage human trial. In every case there have been significant, positive outcomes; absent any adverse events (side effects) of any consideration. Unlike virtually all other drugs working on difficult central nervous system (CNS) diseases, blarcamesine is utterly safe.
Then, there are the statistical analyses in all of the trials. All very positive, with strong, accepted statistical significance. Positive clinical results produced by blarcamesine are in no way merely random happenstance. Blarcamesine really does produce very safe and favorable clinical outcomes. Nothing random about them at all.
Then, there is the issue of how this one particular drug might be able to so effectively and safely produce favorable therapeutic outcomes in such a diversity of CNS diseases. How the drug could work in both Parkinson's disease dementia and Alzheimer's seems plausible; they have similar debilitations of cognition. But Rett is wholly different, as are most of the other target diseases in the blarcamesine pipeline. Five to eight years ago all of this was still a mystery. No longer. The unique and multiple mechanisms of action (MOAs) of blarcamesine are now known and understood; as depicted and described in the presentation.
Consider; the information presented in the new Anavex presentation shows that blarcamesine beats, by a long margin, any and all other drugs now used to treat the listed CNS diseases. Blarcamesine has no competition. The few other drugs treating CNS diseases work against "downstream" disease processes and outcomes; and not very well. Blarcamesine, by itself, is in a whole new CNS drug category, where by its profound activation of the sigma-1 receptor protein, "upstream" in neuropathology reaction pathways, a diversity of downstream pathologies are "fixed," obviated. No other drug like it.
The presentation tells in some detail the actual molecular science of blarcamesine. It is not intended to affect or shape the behaviors of stock investors working to make and take trading profits. The presentation will be useful only to those who take a long-term view of Anavex Life Sciences Corp, showing the details of the science of blarcamesine that will make Anavex a major global pharmaceutical. No doubts.
-
Thorkild, han var biologi lærer men en talentfuld en(sikket nok), så med en vis forståelse af hvordan det hele hænger sammen.
Market tror stadig ikke rigtigt på Anavex med nuværende kurs, desværre.
Selvfølgelig skal man værre lidt skeptisk, tro kan ment gøre en blind.
Men de har jo ikke fejlet noget som helst indtil nu, det er også værd at tænke over.
-
Tak. Betryggende at vide lidt mere om mandens baggrund og grundlag for hans konklusioner.
-
Mener faktisk han er eller var på universitetsniveau.
Han har efterfølgende lavet dette indlæg, hvor jeg dog tror at han skyder over mål
Anavex Life Sciences Corp (AVXL): Number of potential blarcamesine users....
falconer66a: Number of potential blarcamesine users. For some future Anavex revenues calculations some numbers have to be used. One of the first ones is the tot...
InvestorsHub (investorshub.advfn.com)
Men nu var det også biologi dar var specialet
Tryk evt på hans alias og vælg latest post. Så er der indlæg efter indlæg på højt niveau
Kursen ... roller coaster
-
Der er helt sikkert tale om en investor/ekspert, der IKKE er blottet for visioner
Minder lidt om en "unbiased SAVA analyse" forfattet af en langsigtet SAVA investor :), jeg læste på Seeking Alpha igår. -
-
Solsen...Dine seneste indlæg og videoer løfter gevaldigt på kursen i dag.
-
Anavex. Nu vi er i gang med videoer.
Anerkendte Randi Hagermann om Anvex 2-73 i RETT:
(Hende der selv gerne vil medicineres med 2-73)38:24 - 42:00
og
1:15:58 - 1:18:20
Indslag vedr. opstart af 2-73 i RETT piger 5-18 år:
-
Anavex Mere direkte link.
Anerkendte Randi Hagermann om Anvex 2-73 i RETT:
(Hende der selv gerne vil medicineres med 2-73)38:24 - 42:00
og
1:15:58 - 1:18:20
-
The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer's
Nævnt er: 2-73 og AF710B (3-71) er Anavex. Den sidste T-817 er vidst nok Fujifilm. Hmm jeg ejer Fuji kameraer, ha-ha.
Der ser ud til at man nu bliver mere og mere overbevidst om at σ-1R agonists er vejen frem, hvad der er rigtigt godt for os her på tråden.
The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer's - PubMed
We propose a mechanism through which the activation of σ-1R and autophagy could alter amyloid precursor protein processing to inhibit amyloid-β production by reconstituting cholesterol and gangliosides in the lipid raft to offer neuroprotection against AD. Future AD treatment could involve the combi …
PubMed (pubmed.ncbi.nlm.nih.gov)
-
Anavex Rart at det er andre end os nørder og IHUB banden, der har set sammenhænget i videnskaben og lyset
Understøtter 100 % det Anavex ser afspejlet i deres resultater.
Tror bare ikke største del af markedet helt har fattet det endnu!
SAVA/ANAVEX
SAVA med deres ikke placebo kontrollerede og kortvarige lille forsøg, har jo vist fine resultater.
Kan dog ikke se, at de på nogen måder, trods påholdende promovering, kan udgå et rigtig placebo kontrolleret forsøg, for at blive endelig godkendt.
Selvom resultaterne er gode, så mangler de både placebo elementet og en længerevarende bivirkningsprofil!
Deres prissætning på hele 3,6 milliarder $, uden endnu at have startet et fase 3 forsøg synes meget højt!
( Mit foreløbige pejlemærke er samme MC som SAVA , svarende til kurs 65$ )Anavex har alt det SAVA mangler og er derfor flere år foran SAVA.
Har det dog fint med, at både SAVA og ANVS giver markedet og aktionærerne mod på at investerer i Alzheimer segmentet - efter Biogen/FDA skandalen. - hele sektoren kunne muligvis ellers være blevet black listet.Som ved COVID-19, har alle selskaber med en god vaccine jo også fået deres del af markedet.
Dette vil helt sikkert også ske på Alzheimer/CNS området.Så et positivt syn på Alzheimer segmentet, vil/har også smitte af på vores lille Anavex - de skal bare have noget der virker.
Er nu mere end tidligere overbevist om, at Anavex også nok skal leverer varen!
NB:
Har både SAVA og ANVS - flere heste/follow the money! -
Jones trading beholder deres kurs mål på Anavex til 50$, udkom i går fra 5 stjernet analyst Soumit Roy
Det kan vi godt leve med til en start.
-
Rat med denne heppekor - men hvor er Boersboe ? Har han taget gevinsten og forladt os?
Også jeg trænger til at komme lidt ned på jorden, - kan ikke rigtig tro man kan kurere sygdommene ved blot at indtage en pille daglig.
Så sigt bliver det måske en form for kombinationsbehandling er min fornemmelse, men Anavex vil sikkert være en part.
-
Anavex Kursmål 50 $ og Anavex narturligvis i rødt.
Soumit Roy kender jeg ikke, men han har åbenbart en høj rating.
Så meget naturligt vi skal ned:)
Vi følger SAVA overdreven ned og hænger i bremsen, når SAVA stiger.According to TipRanks.com, JonesTrading analyst Soumit Roy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 35.1% and a 42.53% success rate.
Boersboe holder nok ferie, som vi andre snart - så du må nøjes med IHUB klubben Hyst eller andre nørder:)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind